[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-vascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-vascular-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,59,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100630094","a-study-of-clinical-implications-of-pulmonary-vascular-disease-in-valvular-heart-disease-100630094",false,"NCT07483203","A Study Of Clinical Implications Of Pulmonary Vascular Disease In Valvular Heart Disease","Clinical Implications of Pulmonary Vascular Disease in Valvular Heart Disease","Inclusion Criteria:\n\n* ≥18 years old; AND\n* Scheduled for valve procedures\n\nExclusion Criteria:\n\n* Congenital heart disease (except for bicuspid aortic valve), OR\n* Carcinoid heart disease, OR\n* Valvular mass, OR\n* Endocarditis, OR\n* Any other condition that, in the opinion of the investigator, would impair their ability to complete the study","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterize pulmonary hemodynamic profiles, with a focus on PVR subtypes, in patients with left-sided valvular heart disease undergoing aortic or mitral valve intervention, and to identify patterns predicting reversibility of TR and RV dysfunction.",[24,25],"Pulmonary Vascular Disease","Valvular Heart Disease","RECRUITING","2026-06-16",{"date":29,"type":30},"2026-06-18","ACTUAL",{"date":32,"type":30},"2026-04-28",{"date":34,"type":20},"2028-05",{"name":36,"class":37},"Mayo Clinic","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":38},"100511143","pulmonary-hypertension-in-left-heart-disease-100511143","NCT05935605","Pulmonary Hypertension in Left Heart Disease","Comparison of Noninvasively-Obtained Echocardiographic Doppler Parameters With Simultaneously-Measured Invasive Hemodynamics in Patients Referred for Right Heart Catheterization","Inclusion Criteria:\n\n* Patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason.\n* Left Heart Disease, defined as one (or more) of the following:\n\n  * Symptomatic HFpEF, defined by signs and symptoms of HF (dyspnea, fatigue), normal left ventricular (LV) EF (≥50% within 12 months of enrollment), and objective evidence of HF fulfilling at least one of the following criteria: Prior hospitalization for decompensated HF treated with intravenous diuretics; Invasively verified HFpEF defined by pulmonary capillary wedge pressure (PCWP) of ≥15 mmHg at rest and\u002For ≥25 mmHg during exercise; Clinical diagnosis of HFpEF that does not meet criteria i. or ii. but verified with NTproBNP\\>300 pg\u002Fml in sinus rhythm or \\>900 pg\u002Fml in AF; H2FPEF score ≥6 or HFA-PEFF score≥5 according to current guidelines.\n  * Symptomatic HFrEF, defined by defined by signs and symptoms of HF (dyspnea, fatigue) and reduced EF (\\\u003C50%).\n  * Symptomatic valvular heart disease (VHD), defined by signs and symptoms of HF (dyspnea, fatigue) in tandem with clinically significant aortic or mitral valve disease (regurgitation and\u002For stenosis).\n\nExclusion Criteria:\n\n* Patient inability or unwillingness to undergo noninvasive echocardiography, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case.\n* WSPH Group 1 Pulmonary hypertension or PH (Pulmonary arterial hypertension; including congenital heart disease)\n* Group 3 PH (Hypoxia\u002FLung disease-related PH)\n* Group 4 PH (Thromboembolic PH)\n* Group 5 PH (Miscellaneous)\n* Clinically significant parenchymal lung disease, hypoxemia, or lung infection\n* Amyloid\u002Finfiltrative cardiomyopathy\n* Acute Myocarditis\n* Acute coronary syndrome or revascularization within 90 days\n* Use of PH-specific drugs\n* Constrictive pericarditis\n* High output heart failure\n* HF hospitalization within the preceding 30 days\n* Severe or greater aortic (AVA \\\u003C 1.0 cm2, Mean Gradient \\> 40 mmHg) or severe mitral (MVA \\\u003C 1.0 cm) stenosis\n* Inability or unwillingness to exercise\n* Inadequate echocardiographic imaging windows\n* Inability or unwillingness to cooperate with breath holding",{"count":47,"type":20},3000,"The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.",[50,24,51],"Pulmonary Hypertension","Left Heart Disease","2026-03-03",{"date":54,"type":30},"2026-03-05",{"date":56,"type":30},"2023-07-20",{"date":34,"type":20},{"name":36,"class":37},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":38},"100531074","contrast-echocardiography-during-exercise-to-assess-pulmonary-blood-volume-100531074","NCT06195059","Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume","Assessment of Pulmonary Blood Volume Using Contrast Echocardiography During Exercise","Inclusion Criteria:\n\n* Patients referred to the cardiac catheterization laboratory for invasive exercise right heart catheterization for evaluating exertional dyspnea. Investigators will include patients with normal or low EF, and across the spectrum of pulmonary hypertension severity.\n\nExclusion Criteria:\n\n* Patient inability or unwillingness to undergo echocardiography including a contrast method, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case.\n* Prior adverse reaction to echo contrast administration",{"count":67,"type":20},800,"The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without heart failure and pulmonary vascular disease.",[70,24],"Heart Failure","2025-08-11",{"date":73,"type":30},"2025-08-14",{"date":75,"type":30},"2024-07-30",{"date":77,"type":20},"2026-11",{"name":36,"class":37},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":90,"studyType":21,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100228319","pediatric-pulmonary-hypertension-network-pphnet-informatics-registry-100228319","NCT02249923","Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry","PPHNet","Inclusion Criteria:\n\n* The subject's age of onset of pulmonary hypertension must be prior to age 18 years\n* The person providing consent must be able to read either Spanish or English.\n* The subject (and\u002For parent\u002Flegal guardian) must be able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with pulmonary hypertension after age 18\n* Refusal to sign informed consent","1 Day","21 Years",{"count":89,"type":20},2500,"5 Years","Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.",[24,93],"Pulmonary Arterial Hypertension",[95,96,97,98],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Vascular Disease (PVD)","Registry","Pediatric","2025-03-10",{"date":101,"type":30},"2025-03-13",{"date":103,"type":4},"2014-10",{"date":105,"type":20},"2031-12",{"name":107,"class":37},"New York Medical College",14]